BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the
"Company"), a medical technology company commercializing an
innovative signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that it is installing a PURE EP™ System
for an evaluation at the HCA Healthcare-operated Westside Regional
Medical Center in Plantation, FL.
Westside Regional Medical Center is an award-winning 250-bed
hospital recognized for providing a wide array of services to the
residents of Broward County, South Florida, and visitors from
around the world. The hospital’s electrophysiology program is one
of the most frequented in Broward County, offering advanced
diagnostic services and multiple modalities for diagnosing and
treating arrhythmia.1. In addition to its comprehensive
cardiovascular services, Westside Regional Medical Center is
certified as a Comprehensive Stroke Center by the Agency for Health
Care Administration (ACHA). Westside Regional Medical Center is a
facility of HCA East Florida, the most extensive healthcare system
in Eastern Florida and an affiliate of Hospital Corporation of
America (HCA). HCA East Florida has 14 hospitals, multiple
ambulatory surgery centers, physician practices, free-standing
emergency care facilities, and a supply chain center, and an
integrated regional lab.2
“Our new installation agreement with Westside Regional Medical
Center increases our clinical reach across the state, with an
installation in both the north and south regions of Florida. We are
thrilled to partner with another leading HCA Healthcare-operated
institution and continue to solidify our commitment to arrhythmia
patient care across the state of Florida,” commented Kenneth L.
Londoner, Chairman and CEO of BioSig Technologies, Inc.
To date, 73 physicians have completed over
1750 patient cases with the PURE EP™ System. The
Company is in a focused commercial launch of the PURE EP™ System in
the Northeast, Texas, and Florida. The Company’s most recent
evaluation adds to its clinical footprint in Florida, which also
includes Mayo Clinic’s Florida Campus, a national Medical Center of
Excellence.
Clinical data acquired by the PURE EP™ System in a multi-center
study at Texas Cardiac Arrhythmia Institute at St. David’s Medical
Center, Mayo Clinic Jacksonville and Massachusetts General Hospital
was recently published in the Journal of Cardiovascular
Electrophysiology and is available electronically with open access
via the Wiley Online Library. Study results showed 93% consensus
across the blinded reviewers with a 75% overall improvement in
intracardiac signal quality and confidence in interpreting PURE EP™
signals over conventional sources.
About 2,300 Americans die from heart disease each day – an
average of one death every 38 seconds3. In 2016, 1.6 million Texas
adults reported that they had been diagnosed with heart disease or
stroke4. There were 336,462 hospitalizations of adult Texans
related to heart disease in 2016, at an age-adjusted rate of 124.0
per 10,000 adults5. The direct and indirect costs of heart disease
and stroke in the U.S. are estimated to be $329.7 billion, and the
cost is projected to increase to $749 billion by 20356.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP™ System is a computerized
system intended for acquiring, digitizing, amplifying, filtering,
measuring and calculating, displaying, recording, and storing
electrocardiographic and intracardiac signals for patients
undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
1 Arrhythmia Specialties - Westside Regional Medical Center:
westsideregional.com
2 Hospital News and Healthcare Report – 2020:
southfloridahospitalnews.com
3 Heart disease and stroke statistics – 2018 update: a report
from the American Heart Association
4 Texas Behavioral Risk Factor Surveillance System Public Use
Data File, 2016, Center for Health Statistics, Texas Department of
State Health Services
5 Texas Hospital Inpatient Discharge Public Use Data, Texas
Health Care Information Collection, 2016, Center for Health
Statistics, Texas Department of State Health Services
6 Heart disease and stroke statistics – 2018 update: a report
from the American Heart Association
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jul 2023 to Jul 2024